Jun 30, 2022

Enliven Therapeutics Q2 2022 Earnings Report

EPS
-$1.76
Previous year: -$2.96
-40.5%
Research and Development Expenses
$7.94M
General and Administrative Expenses
$1.08M
Cash and Equivalents
$92.5M
Previous year: $66.8M
+38.5%
Total Assets
$64.7M
Previous year: $72.5M
-10.8%

Enliven Therapeutics

Enliven Therapeutics